A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.

Trial Details

NCT ID
NCT06481592
Phase
PHASE2
Sponsor
Iovance Biotherapeutics, Inc.
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Lifileucel
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Los Angeles, California, United States|34.05223,-118.24368
  • Orlando, Florida, United States|28.53834,-81.37924
  • Tampa, Florida, United States|27.94752,-82.45843
  • Augusta, Georgia, United States|33.47097,-81.97484

Key Eligibility Criteria

  • Participants must have a histologically confirmed diagnosis of endometrial carcinoma. All histologies, including carcinosarcoma, will be allowed. U…
  • Participants who have received the following previous therapies:
  • At least 1 but no more than 4 lines of prior systemic therapy with no more than 2 lines of chemotherapy in any setting (ie, neoadjuvant or adjuvant…
  • Participants have received platinum-based chemotherapy and anti-PD-1/PD-L1 therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →